Home > Insider Trading > Filing (0001567619-21-016870)

Filing Details

Accession Number:: 0001567619-21-016870
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-09-08 21:02:13
Reporting Period:: 2021-09-07

Accepted Time:: 2021-09-08 21:02:13
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1704292	Zai Lab Ltd	ZLAB	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1835824	Harald Reinhart	C/O Zai Lab Limited 4560 Jinke Road, Bldg 1, 4Th Floor Pudong, Shanghai F4 201210	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Ordinary Shares	Acquisiton	2021-09-07	10,000	$3.00	10,000	No	4	M	Direct
Ordinary Shares	Disposition	2021-09-07	100	$143.00	9,900	No	4	S	Direct
Ordinary Shares	Disposition	2021-09-07	200	$146.98	9,700	No	4	S	Direct
Ordinary Shares	Disposition	2021-09-07	300	$148.69	9,400	No	4	S	Direct
Ordinary Shares	Disposition	2021-09-07	2,000	$150.41	7,400	No	4	S	Direct
Ordinary Shares	Disposition	2021-09-07	6,600	$151.28	800	No	4	S	Direct
Ordinary Shares	Disposition	2021-09-07	800	$152.11	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Stock Options (Right to Buy)	Disposition	2021-09-07	10,000	$0.00	10,000	$3.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
23,334		2027-05-12	No	4	M	Direct

Footnotes

The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
Reflects a weighted average sale price of $146.98 per share, at prices ranging from $146.66 to $147.30 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Reflects a weighted average sale price of $148.69 per share, at prices ranging from $148.23 to $148.92 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Reflects a weighted average sale price of $150.41 per share, at prices ranging from $149.80 to $150.78 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Reflects a weighted average sale price of $151.28 per share, at prices ranging from $150.84 to $151.82 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Reflects a weighted average sale price of $152.11 per share, at prices ranging from $151.85 to $152.50 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
The options vest in equal annual installments over four years beginning on 5/12/2018, the first anniversary of the date of grant.